Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-001)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2013 by Albert Einstein College of Medicine of Yeshiva University
Sponsor:
Information provided by (Responsible Party):
Albert Einstein College of Medicine of Yeshiva University
ClinicalTrials.gov Identifier:
NCT02006264
First received: November 19, 2013
Last updated: December 5, 2013
Last verified: December 2013

November 19, 2013
December 5, 2013
Not Provided
December 2014   (final data collection date for primary outcome measure)
  • Genitourinary events Grade 1 or higher judged to be related to study product. [ Time Frame: 14 days of vaginal ring use ] [ Designated as safety issue: Yes ]
    Adverse Events as defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events
  • Adverse events Grade 2 or higher [ Time Frame: 14 days of vaginal ring use ] [ Designated as safety issue: Yes ]
    Adverse Events as defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events
Same as current
Complete list of historical versions of study NCT02006264 on ClinicalTrials.gov Archive Site
  • TDF and TFV concentrations in plasma and genital secretions (cervix and vagina) [ Time Frame: Days 1, 3, 7 and 14 after ring insertion and 2 and 7 days after ring removal. ]
    TDF and TFV concentrations in plasma and genital secretions pharmacokinetics (C-Max, T-Max and AUC)
  • TFV and tenofovir diphosphate (TFV-DP) concentrations in PBMCs [ Time Frame: Days 1, 3, 7 and 14 after ring insertion and 2 and 7 days after ring removal. ]
    TFV and tenofovir diphosphate (TFV-DP) concentrations in PBMCs pharmacokinetics (C-Max, T-Max and AUC)
  • TFV and TFV-DP concentrations in cervical tissue [ Time Frame: 14 days after vaginal ring insertion ]
    TFV and TFV-DP concentrations in cervical tissue pharmacokinetics (C-Max, T-Max and AUC)
Same as current
Not Provided
Not Provided
 
Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring
Phase 1 Safety and Pharmacokinetic Study of Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring

This prospective, randomized, single-blinded, placebo controlled trial will examine the safety and pharmacokinetics (PK) of a polyurethane tenofovir disoproxil fumarate (TDF) vaginal ring when used continuously for 14 consecutive days.

The primary objective is to assess the safety of TDF vaginal rings when used continuously for 14 days by healthy, HIV-uninfected, sexually abstinent women, as compared with a placebo vaginal ring.

Not Provided
Interventional
Phase 1
Allocation: Randomized
HIV
  • Drug: TDF Intravaginal Ring
  • Drug: Placebo Intravaginal Ring
  • Active Comparator: TDF Intravaginal Ring
    Intervention: Drug: TDF Intravaginal Ring
  • Placebo Comparator: Placebo Intravaginal Ring
    Intervention: Drug: Placebo Intravaginal Ring

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
Not Provided
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • General good health (by volunteer history and per investigator discretion) without any clinically significant systemic disease (including, but not limited to significant liver disease/hepatitis, gastrointestinal disease, kidney disease, thyroid disease, osteoporosis or bone disease, and diabetes)
  • Willing to give voluntary consent, sign an informed consent form and comply with study procedures as required by the protocol
  • HIV-uninfected based on testing performed by study staff during screening procedures
  • Using low dose combined (estrogen and progesterone-containing) oral contraceptive pills (does not include extended-cycle, 24 and 28-day active pill regimens). Per participant report must be using this contraceptive method with no change in the prior 3 months and intending to use same method for the duration of study participation.
  • Currently have a regular 28-day menstrual cycle on combined oral contraceptive pills.
  • Normal Pap test at screening or appropriately documented history of Pap test and completed follow-up of any abnormal pap tests consistent with American Congress of Obstetricians and Gynecologists (ACOG) practice guidelines #99 and #109.
  • Agrees not to participate in other research studies involving drugs, medical devices, or vaginal products for the duration of study participation.
  • Able and willing to refrain from inserting any non-study vaginal products or objects into the vagina for the 48 hours prior to Visit 2 throughout the duration of the study.
  • Able and willing to abstain from oral, vaginal and anal sex for 48 hours prior to Visit 2 throughout the duration of the study.

Exclusion Criteria:

Women must meet none of the following criteria prior to genital sampling at Visit 2:

  • Known adverse reaction to polyurethane or to any components of the study product or allergy to both silver nitrate and Monsel's solution.
  • Hepatitis B infection (defined as positive hepatitis B surface antigen).
  • Chronic, recurrent, and/or acute vulvar or vaginal symptoms (pain, irritation, spotting, etc.).
  • Known bleeding disorder that could lead to prolonged or continuous bleeding with biopsy.
  • Pregnant or intending to become pregnant during the period of study participation.
  • Currently breastfeeding or having breastfed an infant in the last two months, or planning to breastfeed during the course of the study.
  • Menopause.
  • History of unexplained or unresolved intermenstrual bleeding in the 3 months prior to screening.
  • History of gynecological procedures (including genital piercing) on the external genitalia, vagina or cervix in the last 14 days.
  • Hysterectomy.
  • Use and/or anticipated use during the study period of an intravaginal or intrauterine device.
  • Systemic use in the last 2 weeks or anticipated use during the study period of any of the following: corticosteroids, antibiotics, antifungals, antivirals, anticoagulants or antiretrovirals.
  • Grade 1 or higher laboratory abnormality, per the August 2009 update of the Division of AIDS, National Institute of Allergy and Infectious Disease (DAIDS) Table for Grading the Severity of Adverse Events (AEs).
  • In the last six months, diagnosed with or treated for any sexually transmitted infection (STI).
  • Reproductive tract infection (RTI) or pelvic inflammatory disease (PID) requiring treatment per current CDC guidelines at Screening or Enrollment.
  • Positive test for Trichomonas vaginalis, Neisseria gonorrhea or Chlamydia trachomatis at screening.
  • Reactive test for syphilis at screening.
  • At Screening or Enrollment, has a clinically apparent Grade 1 or higher pelvic exam finding (observed by study clinician or designee) per the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Addendum 1, Female Genital Grading Table for Use in Microbicide Studies.
Female
18 Years to 45 Years
Yes
Contact: Lilia Espinoza 718-430-3061 lilia.espinoza@einstein.yu.edu
United States
 
NCT02006264
2013-329
Not Provided
Albert Einstein College of Medicine of Yeshiva University
Albert Einstein College of Medicine of Yeshiva University
Not Provided
Not Provided
Albert Einstein College of Medicine of Yeshiva University
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP